Condition: Anal Cancer Patients · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Radiochemotherapy is the standard treatment for neoplasms of the anal canal with excellent rates of local control and preservation of the anal sphincter. However, patients may experience a deterioration of quality of life related to sequelae of the treatment particularly at intestinal, anal sphincter and sexual level. Few studies to date have documented patient-reported outcomes (PROs) in this area. The aim of this observational study is to verify the quality of life (QOL) of the patients by means of self-completed questionnaires.
This description comes directly from the study's public registry record.
Stefania Manfrida, MD · 0039 0630154434 · stefania.manfrida@policlinicogemelli.it
Stefania Manfrida · +390630155701 · stefania.manfrida@policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Universitario A. Gemelli IRCCS | Rome, Lazio, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06364579